{"id":"colforsin-daropate","rwe":[{"pmid":"39561220","year":"2024","title":"Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas.","finding":"","journal":"Science signaling","studyType":"Clinical Study"},{"pmid":"23625548","year":"2013","title":"Retraction note to: High-dose colforsin daropate increases diaphragmatic contractility in dogs.","finding":"","journal":"Canadian journal of anaesthesia = Journal canadien d'anesthesie","studyType":"Clinical Study"},{"pmid":"23439837","year":"2013","title":"The effect of inhaled colforsin daropate on contractility of fatigued diaphragm in dogs. Anesth Analg 2003;96:1032-4. Retraction.","finding":"","journal":"Anesthesia and analgesia","studyType":"Clinical Study"},{"pmid":"23439833","year":"2013","title":"Colforsin daropate improves contractility in fatigued canine diaphragm. Anesth Analg 2001;92:762-6. Retraction.","finding":"","journal":"Anesthesia and analgesia","studyType":"Clinical Study"},{"pmid":"22610350","year":"2012","title":"Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway.","finding":"","journal":"American journal of physiology. Lung cellular and molecular physiology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Adenylate cyclase type 1","category":"target"},{"label":"ADCY1","category":"gene"},{"label":"ADCY8","category":"gene"},{"label":"SLC2A1","category":"gene"},{"label":"Active","category":"status"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Cardiotonic Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"colforsin dapropate","offLabel":[],"synonyms":["colforsin dapropate hydrochloride","colforsin dapropate","colforsin daropate hydrochloride","colforsin daropate","colforsin dapropate HCl","colforsin daropate HCl"],"timeline":[],"approvals":[],"brandName":"Colforsin Dapropate","ecosystem":[],"mechanism":{"target":"Adenylate cyclase type 1, Adenylate cyclase type 8, Solute carrier family 2, facilitated glucose transporter member 1","targets":[{"gene":"ADCY1","source":"DrugCentral","target":"Adenylate cyclase type 1","protein":"Adenylate cyclase type 1"},{"gene":"ADCY8","source":"DrugCentral","target":"Adenylate cyclase type 8","protein":"Adenylate cyclase type 8"},{"gene":"SLC2A1","source":"DrugCentral","target":"Solute carrier family 2, facilitated glucose transporter member 1","protein":"Solute carrier family 2, facilitated glucose transporter member 1"},{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"modality":"Small Molecule","explanation":"Think of cAMP as a messenger that helps cells respond to signals. When adenylate cyclase type 1 is activated, it produces more cAMP, which can help cells do their job more efficiently. This can lead to various effects depending on the cell type and the condition being treated.","oneSentence":"Colforsin Dapropate works by activating adenylate cyclase type 1, which increases the production of cyclic AMP (cAMP) within cells.","technicalDetail":"Colforsin Dapropate acts as a direct activator of adenylate cyclase type 1, increasing the conversion of ATP to cyclic AMP (cAMP), a key second messenger involved in cellular signaling pathways."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Colforsin_daropate","title":"Colforsin daropate","extract":"Colforsin daropate is a cardiovascular drug used to treat acute heart failure. Chemically, it is a carboxylic ester derived from the condensation of forskolin (colforsin) with N,N-dimethyl-β-alanine."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/729","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=colforsin daropate","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Colforsin_daropate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:16:21.567683","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"colforsin daropate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"007852","UNII":"1196KQZ976","CHEBI":"CHEBI:31429","VANDF":"4033874","INN_ID":"5326","UMLSCUI":"C0909725","ChEMBL_ID":"CHEMBL52606","KEGG_DRUG":"D01697","DRUGBANK_ID":"DB02587","PUBCHEM_CID":"444029","SECONDARY_CAS_RN":"113462-26-3","MESH_DESCRIPTOR_UI":"D005576","MESH_SUPPLEMENTAL_RECORD_UI":"C122001"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":36,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 Nov 19","pmid":"39561220","title":"Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas.","journal":"Science signaling"},{"date":"2013 Jun","pmid":"23625548","title":"Retraction note to: High-dose colforsin daropate increases diaphragmatic contractility in dogs.","journal":"Canadian journal of anaesthesia = Journal canadien d'anesthesie"},{"date":"2013 Mar","pmid":"23439837","title":"The effect of inhaled colforsin daropate on contractility of fatigued diaphragm in dogs. Anesth Analg 2003;96:1032-4. Retraction.","journal":"Anesthesia and analgesia"},{"date":"2013 Mar","pmid":"23439833","title":"Colforsin daropate improves contractility in fatigued canine diaphragm. Anesth Analg 2001;92:762-6. Retraction.","journal":"Anesthesia and analgesia"},{"date":"2012 Jul","pmid":"22610350","title":"Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway.","journal":"American journal of physiology. Lung cellular and molecular physiology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Colforsin Dapropate, also known as colforsin daropate, is a small molecule modality targeting adenylate cyclase type 1. Its exact drug class is unknown, and it has not been approved by the FDA. The current owner of Colforsin Dapropate is not specified. It is used to treat certain conditions, but specific indications are not provided. The commercial status, half-life, bioavailability, and generic manufacturers of Colforsin Dapropate are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}